Arvinas (NASDAQ:ARVN) Insider Noah Berkowitz Sells 5,685 Shares

Arvinas, Inc. (NASDAQ:ARVN) insider Noah Berkowitz sold 5,685 shares of the stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $11.89, for a total transaction of $67,594.65. Following the completion of the sale, the insider owned 163,938 shares in the company, valued at $1,949,222.82. This represents a 3.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Arvinas Stock Performance

NASDAQ ARVN opened at $11.82 on Thursday. Arvinas, Inc. has a 52 week low of $5.90 and a 52 week high of $19.40. The stock’s 50 day moving average price is $12.38 and its two-hundred day moving average price is $10.33. The stock has a market capitalization of $759.08 million, a price-to-earnings ratio of -14.59 and a beta of 1.88.

More Arvinas News

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: Company webcast scheduled for Feb 24, 2026 to report Q4 and full‑year 2025 results and provide a corporate update — a clear near‑term catalyst that may drive volatility and give management a chance to reset expectations or highlight pipeline progress. Arvinas to Report Q4 and Full Year 2025 Financial Results
• Neutral Sentiment: Short‑interest data in recent reports shows 0 shares (days‑to‑cover 0.0), which appears to be a data anomaly and is unlikely to reflect meaningful changes in short positioning; treat the short‑interest figures with caution.
• Neutral Sentiment: Technical/market context — ARVN’s market cap is roughly $759M, the stock is trading below its 50‑day SMA (~$12.40) but above its 200‑day SMA (~$10.32). These levels matter for momentum/technical traders ahead of the earnings webcast.
• Negative Sentiment: Insider selling from multiple senior executives on Feb 13 — CEO Randy Teel (4,403 shares), CFO Andrew Saik (5,134 shares), CAO David K. Loomis (1,016 shares) and insider Noah Berkowitz (5,685 shares) sold stock at an average price of $11.89, each reducing their holdings roughly 2.8–3.4%. Clustered insider sales by top officers can pressure sentiment even if sizes are modest. SEC filings: CAO sale (Loomis Form 4), Noah Berkowitz sale (Berkowitz Form 4), Andrew Saik sale (Saik Form 4), Randy Teel sale (Teel Form 4).

Analysts Set New Price Targets

Several brokerages have recently commented on ARVN. Stephens raised their target price on shares of Arvinas from $14.00 to $15.00 and gave the stock an “overweight” rating in a report on Monday, November 10th. Wedbush reiterated a “neutral” rating and set a $9.00 price objective on shares of Arvinas in a research report on Thursday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arvinas in a research note on Monday, December 22nd. BTIG Research boosted their price objective on shares of Arvinas from $10.00 to $14.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Finally, Barclays increased their price objective on shares of Arvinas from $16.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. Ten analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $13.12.

Institutional Trading of Arvinas

Several institutional investors have recently made changes to their positions in the company. Armistice Capital LLC boosted its holdings in Arvinas by 50.0% during the fourth quarter. Armistice Capital LLC now owns 1,800,000 shares of the company’s stock worth $21,348,000 after purchasing an additional 600,000 shares during the last quarter. TCG Crossover Management LLC bought a new position in shares of Arvinas during the 3rd quarter worth approximately $13,780,000. Geode Capital Management LLC boosted its stake in shares of Arvinas by 3.1% in the 2nd quarter. Geode Capital Management LLC now owns 1,585,092 shares of the company’s stock worth $11,668,000 after buying an additional 48,296 shares during the last quarter. Qube Research & Technologies Ltd boosted its stake in shares of Arvinas by 154.8% in the 3rd quarter. Qube Research & Technologies Ltd now owns 1,486,864 shares of the company’s stock worth $12,668,000 after buying an additional 903,337 shares during the last quarter. Finally, Acadian Asset Management LLC grew its holdings in shares of Arvinas by 791.1% in the second quarter. Acadian Asset Management LLC now owns 1,427,832 shares of the company’s stock valued at $10,498,000 after acquiring an additional 1,267,593 shares in the last quarter. Institutional investors own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.